

## Full-length article

# Cysteinyl leukotriene receptor 1 is involved in *N*-methyl-*D*-aspartate-mediated neuronal injury in mice<sup>1</sup>

Qian DING, Er-qing WEI<sup>2</sup>, Yan-jun ZHANG, Wei-ping ZHANG, Zhong CHEN

Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China

## Key words

cysteinyl leukotriene receptor; excitotoxicity; *N*-methyl-*D*-aspartate; leukotriene receptor antagonist; pranlukast; NMDA receptor antagonist; ketamine

<sup>1</sup> Project supported by the National Natural Science Foundation of China (No 30371637).

<sup>2</sup> Correspondence to Prof Er-qing WEI.

Phn 86-571-8820-8224.

Fax 86-571-8820-8022.

E-mail weieq2001@yahoo.com

Received 2006-04-25

Accepted 2006-06-26

doi: 10.1111/j.1745-7254.2006.00438.x

## Abstract

**Aim:** To determine whether cysteinyl leukotriene receptor 1 (CysLT<sub>1</sub> receptor) is involved in *N*-methyl-*D*-aspartate (NMDA)-induced excitotoxic injury in the mouse brain. **Methods:** Brain injury was induced by NMDA microinjection (50–150 nmol in 0.5  $\mu$ L) into the cerebral cortex. The changes in CysLT<sub>1</sub> receptor expression 24 h after NMDA injection and the effects of a CysLT<sub>1</sub> receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed. **Results:** In the NMDA-injured brain, the CysLT<sub>1</sub> receptor mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes. Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT<sub>1</sub> receptor. **Conclusion:** CysLT<sub>1</sub> receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT<sub>1</sub> receptor antagonists, indicating that the increased CysLT<sub>1</sub> receptor is involved in NMDA excitotoxicity.

## Introduction

Excitotoxicity, one important determinant in various diseases of the central nervous system (CNS), is involved in acute ischemic brain injury<sup>[1–3]</sup> and can initiate postischemic inflammation by inducing the expression of pro-inflammatory molecules/mediators<sup>[4–6]</sup>. Mediators in postischemic inflammation include 5-lipoxygenase (5-LOX) metabolites eg, cysteinyl leukotrienes (CysLT, including LTC<sub>4</sub>, LTD<sub>4</sub> and LTE<sub>4</sub>)<sup>[7–11]</sup>. We have recently indicated that in cultured rat primary neurons, *in vitro* ischemic-like injury induces endogenous excitatory amino acid (glutamate) release; the released glutamate activates 5-LOX via the *N*-methyl-*D*-aspartate (NMDA) receptor to produce CysLT, which then induce neuron responses<sup>[12]</sup>. These findings show one aspect of the interaction between 5-LOX/CysLT and excitotoxicity. However, as another aspect, whether the 5-LOX metabolites, CysLT, modulate excitotoxicity is still not clear.

The actions of CysLT are mediated by stimulating their receptors. The cloned CysLT receptors consist of 2 subtypes: CysLT<sub>1</sub> and CysLT<sub>2</sub> receptors; both of them G-protein

coupled receptors<sup>[13]</sup>. The human CysLT<sub>1</sub> receptor is localized in the airway of smooth muscle cells, lung macrophages, mast cells, eosinophils and mononuclear cells as detected by *in situ* hybridization or immunohistochemistry<sup>[14,15]</sup>. We have recently reported that CysLT<sub>1</sub> receptor is primarily expressed in cerebral microvascular endothelial cells, and the expression is induced in the neuron- and glial-appearing cells after traumatic injury<sup>[16]</sup>. Moreover, CysLT<sub>1</sub> receptor antagonists, pranlukast (ONO-1078) and montelukast, possess neuroprotective effects on focal cerebral ischemia in rats and mice<sup>[17–20]</sup>. These findings indicate the involvement of the CysLT<sub>1</sub> receptor in brain injury. In addition, we found that pranlukast protected against global cerebral ischemia in rats and inhibited the increased expression of the NMDA receptor subunit NR2A, suggesting an interaction between CysLT<sub>1</sub> and NMDA receptors<sup>[19]</sup>. As indirect evidence, pranlukast attenuates brain injury induced by NMDA microinjection into rat cortex, suggesting that the CysLT<sub>1</sub> receptor may modulate NMDA-induced neurotoxicity<sup>[21]</sup>. However, since the CysLT<sub>1</sub> receptor is not expressed in the neurons in a normal brain<sup>[16]</sup>, this modulation should be proven by

direct evidence.

To determine whether and how the CysLT<sub>1</sub> receptor is involved in excitotoxicity, we induced brain injury by NMDA (one of the exogenous excitatory amino acids) microinjection in the cortex. Then we observed CysLT<sub>1</sub> receptor expression and the effect of pranlukast, a selective antagonist of CysLT<sub>1</sub> receptor, in mice. An NMDA receptor antagonist, ketamine, and an antioxidant with neuroprotective effect for cerebral ischemia, edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one)<sup>[22,23]</sup>, were used as controls.

## Materials and methods

**Materials** Pranlukast (ONO-1078) was kindly provided by Dr Masami TSUBOSHIMA (Ono Pharmaceutical Co, Osaka, Japan); NMDA and 2,3,5-triphenylterazolium chloride (TTC) were purchased from Sigma (St Louis, MO, USA); edaravone was obtained from Hangzhou Conba Pharmaceutical Co (Hangzhou, China); ketamine was purchased from Shanghai Bio-Chem Co (Shanghai, China); Trizol for extracting RNA was from Bio Basic Inc (Mississauga, Ontario, Canada); chemicals for RT-PCR were from Takara Co (Kyoto, Japan); polyclonal rabbit anti-human CysLT<sub>1</sub> antibody was purchased from Cayman Chemicals (Ann Arbor, MI, USA); mouse monoclonal antibodies against neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) and FITC-conjugated goat anti-rabbit IgG and Cy3-conjugated goat anti-mouse IgG were from Chemicon (Temecula, California, USA); cultured human umbilical vein endothelial cells (EA.hy926 cells) were provided by Dr Cora-Jean S EDGELL (University of North Carolina, USA) and human neuroblastoma SK-N-SH cells were purchased from the Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China); biotinylated goat anti-rabbit IgG was purchased from Zhongshan Biotech Co (Beijing, China). Other reagents were commercial products with analytic purity.

**NMDA microinjection** Male Kunming mice weighing 25–30 g were purchased from the Shanghai Experimental Animal Center (Shanghai, China; Certificate No 22-001004). The mice were housed under controlled temperature (22±1 °C), 12 h light/12 h dark cycle and allowed free access to food and water. All the experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.

The mice were anesthetized with an intraperitoneal injection of chloral hydrate (400 mg/kg) and immobilized on a stereotaxic frame (SR-5, Narishige, Tokyo, Japan). The dura overlying the parietal cortex was exposed, and NMDA [50–150 nmol in 0.5 µL of sterile 0.1 mol/L phosphate buff-

ered solution (PBS), pH 7.4] or PBS (0.5 µL) alone was injected with a microinjector into the parietal cortex at a site 1.5 mm caudal to the bregma, 4.0 mm from the midline and 0.8 mm below the dural surface<sup>[24]</sup>. Injections were made over a period of 8 min, and the microinjector was left in place for an additional 10 min to minimize the back-flux of NMDA and then removed. The rectal temperature was maintained at 37.0±0.5 °C with a heating pad and a heating lamp during the surgical procedure. After the surgery, the mice were kept in a recovery box with heating lamps to maintain body temperature and then returned to their cages.

To observe the effects of the agents, the mice were intraperitoneally injected with pranlukast (0.01 and 0.1 mg/kg), ketamine (30 mg/kg), edaravone (9 mg/kg), and saline (control) at 30 min before and 30 min after NMDA injection.

**Histopathological examination** The mice were anesthetized with chloral hydrate and decapitated 24 h after NMDA or PBS injection. The brains were quickly removed and cut into 1 mm-thick coronal slices. The slices were stained with 0.5% 2,3,5-triphenylterazolium chloride (TTC) at 37 °C for 30 min in the dark and then fixed by 10% buffered formalin. The stained slices with the caudal facing upwards were photographed with a digital camera (Panasonic CP 230, Matsushita, Fukuoka, Japan) and recorded in a computer. The regions completely lacking TTC-staining were defined as tissue lesions. The lesion and hemisphere area of each slice were quantified using an image analysis program (AanalyPower 1.0, Zhejiang University, Hangzhou, China). The total lesion volume for each brain was calculated by summation of the corrected lesion volumes [lesion area×thickness (1 mm)] of all slices as described by Lin *et al*<sup>[25]</sup>. Hemispheric swelling representing brain edema was indirectly determined as the percentage increase of the lesioned hemisphere volume.

In another series, the mice were anesthetized with chloral hydrate and then perfused transcardially with 4% paraformaldehyde after pre-washing with saline. The brains were removed, post-fixed in the same fixative and embedded in paraffin; 5 µm or 8 µm-thick coronal sections were cut by cryomicrotomy (CM1900, Leica, Wetzlar, Germany). Then the 5 µm-thick sections were stained with hematoxylin and eosin (H&E) for light microscopic examination. The densities of the neurons in the cortex and hippocampal CA1 regions (1.8–2.0 mm caudal from bregma) were counted using the image analysis program described above.

**RT-PCR** The brain tissues (from the region 0.5–2.5 mm caudal from bregma and the corresponding region of the contralateral hemisphere) were dissected on ice and the total RNA was extracted from the tissue samples using Trizol reagents according to the manufacturer's protocol. RNA

purity and yield were determined by UV spectrophotometry (Bio-Rad Smart Spec 3000, Hercules, CA, USA). For cDNA synthesis, aliquots of total RNA (2 µg) were mixed with 0.2 µg random hexamer primer, 20 U RNasin, 1 mmol/L dNTP and 200 U M-MuLV reverse transcriptase in 20 µL of the reverse reaction buffer. The mixture was incubated at 42 °C for 60 min and then at 72 °C for 10 min to inactivate the reverse transcriptase. As a negative control, the reaction was performed with the absence of the reverse transcriptase.

The RT-cDNA template (1 µL) underwent PCR (Bio-Rad, USA) in a 20 µL reaction mixture containing 1×PCR buffer, 200 µmol/L dNTP, 1.5 mmol/L MgCl<sub>2</sub>, 20 pmol of each primer and 0.5 U of *Taq* DNA polymerase. Cycling parameters were as follows: 94 °C for 2 min, followed by 33 cycles of 94 °C for 30 s, 63 °C for 30 s and 72 °C for 30 s, with a final extension step of 72 °C for 10 min. The primer pairs for the mouse CysLT<sub>1</sub> receptor were derived from the published cDNA sequence<sup>[26]</sup> and synthesized by Sangon Biotech Co (Shanghai, China): 5'-CAA CGA ACT ATC CAC CTT CACC-3' as sense and 5'-AGC CTT CTC CTA AAG TTT CCAC-3' as antisense. The primers for β-actin were 5'-GTC GTA CCA CAG GCA TTG TGA TGG-3' as sense and 5'-GCA ATG CCT GGG TAC ATG GTG-3' as antisense. The product sizes were 164 bp and 490 bp, respectively. The PCR products in 10 µL were separated by electrophoresis on a 2% agarose gel containing ethidium bromide and photographed. The optical density of the bands was determined by an image analysis system (Bio-Rad, USA). The amount of CysLT<sub>1</sub> receptor mRNA was calculated as the ratio over β-actin.

**CysLT<sub>1</sub> receptor specific immunohistochemical analysis** To confirm the specificity of the polyclonal rabbit anti-human CysLT<sub>1</sub> receptor antibody used in the immunohistochemical staining of mouse brain tissues, we collected protein samples from normal mouse brains as well as from the cultured human umbilical vein endothelial cells (EA.hy926 cells) and human neuroblastoma SK-N-SH cells for Western blotting analysis. The mouse brain samples were homogenized and cell samples were sonicated in lysis buffer. The lysates were then centrifuged at 15 000×g at 4 °C for 30 min and the supernatant was used. Protein samples (50 µg) were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to the nitrocellulose membranes. Then, the membranes were blocked by 5% bovine serum albumin (BSA) and reacted with a rabbit polyclonal antibody against the CysLT<sub>1</sub> receptor (1:2000) and peroxidase-conjugated goat anti-rabbit IgG (1:2000) after repeated washing. Finally, the protein bands were visualized by enhanced chemiluminescence.

Immunohistochemical detection of the CysLT<sub>1</sub> receptor


was performed on 8 µm-thick coronal sections (1.8–2.0 mm caudal from bregma). After 3 washes with PBS, the sections were incubated with 0.3% hydrogen peroxide in methanol at room temperature for 30 min to block the reactivity of endogenous peroxidase. The sections were washed several times in the PBS, pre-incubated with 5% normal goat serum for 2 h to reduce non-specific staining, and then reacted with the polyclonal rabbit anti-human CysLT<sub>1</sub> receptor antibody (1:150) overnight at 4 °C. Control sections were treated with normal goat serum instead of the primary antibody. After repeated washing in PBS, the sections were reacted for 1 h with the secondary antibody (1:200), biotinylated goat anti-rabbit IgG, followed by reaction for 1 h with avidin-biotin-horseradish peroxidase complex (1:200). Finally, the sections were exposed for 2–5 min to 0.05% 3,3'-diaminobenzidine and 0.03% hydrogen peroxide and examined by a light microscope (Olympus BX51, Olympus, Tokyo, Japan).

To visualize the localization of the CysLT<sub>1</sub> receptor in different cell types, double immunofluorescence was employed. Briefly, non-specific binding of IgG was blocked with 5% normal goat serum for 2 h at room temperature; each section was incubated overnight at 4 °C with a mixture of rabbit polyclonal antibody against the CysLT<sub>1</sub> receptor and mouse monoclonal antibodies against NeuN (a specific marker of neurons) or GFAP (a specific marker of astrocytes). Then, the sections were incubated with the mixture of FITC-conjugated goat anti-rabbit IgG and Cy3-conjugated goat anti-mouse IgG and observed under a fluorescence microscope (Olympus BX51, Japan).

**Statistical analysis** All values are presented as mean±SD. One-way ANOVA (Student-Newman-Keuls) was performed for statistical analysis using the SPSS software package (version 10.0 for Windows; SPSS, Chicago, Illinois, USA). *P*<0.05 was considered statistically significant.

## Results


**Effect of pranlukast on NMDA-induced brain injury** To confirm the involvement of the CysLT<sub>1</sub> receptor in excitotoxicity, we observed the effect of its antagonist pranlukast, on NMDA-induced brain injury in comparison with ketamine and edaravone. NMDA 50, 100, and 150 nmol dose-dependently increased lesion volume (TTC staining) and the lesioned hemisphere volume (indicating brain edema) 24 h after microinjection (*P*<0.01, Figure 1A–1C). Pranlukast 0.1 mg/kg, edaravone 9 mg/kg and ketamine 30 mg/kg significantly attenuated NMDA-induced (150 nmol) injury (*P*<0.05 or 0.01, Figure 1D–1F). The histopathological examination showed that NMDA microinjection induced serious pyknotic



**Figure 1.** NMDA-induced brain lesion and the effect of pranlukast. NMDA (50–150 nmol in 0.5  $\mu$ L of 0.1 mol/L PBS) or PBS alone was microinjected into the parietal cortex (1.5 mm caudal to bregma, 4.0 mm from the midline, and 0.8 mm below the dural surface). Pranlukast (0.01 and 0.1 mg/kg), edaravone (9 mg/kg), ketamine (30 mg/kg) and saline (control) were ip injected 30 min before and 30 min after NMDA injection. Brain slices were stained with 0.5% TTC and photographed at 24 h after NMDA injection. Lesion volume and brain edema (the ratio of left/right hemisphere volumes) were calculated. NMDA dose-dependently increased lesion volume and brain edema (A–C). NMDA-induced (150 nmol) lesion was attenuated by pranlukast 0.1 mg/kg, as well as edaravone and ketamine (D–F). Mean $\pm$ SD. *n*=6–14 mice per group. <sup>e</sup>*P*<0.01 vs PBS group; <sup>e</sup>*P*<0.05, <sup>f</sup>*P*<0.01 vs control group (NMDA alone); one-way ANOVA. nd, not detectable. Scale bar=2 mm.

nuclei and deeply stained cells in the ipsilateral cortex and hippocampal CA1 [not CA3 and dentate gyrus (DG)] region as detected by H&E staining (Figure 2A,2B), and significantly reduced the density of neurons in the cortex (50–150 nmol; Figure 2C) and hippocampal CA1 region (100 and 150

nmol; Figure 2D). Pranlukast (0.1 mg/kg), edaravone (9 mg/kg) and ketamine (30 mg/kg) significantly attenuated NMDA (150 nmol)-reduced density in the cortex (Figure 2E) or hippocampal CA1 region (Figure 2F). These results indicates that the protective effect of pranlukast at 0.1 mg/kg on




**Figure 2.** Effect of pranlukast on neuron density in the cortex and hippocampal CA1 region 24 h after NMDA microinjection. Representative microphotographs show the morphological changes induced by NMDA 150 nmol in the cortex (A) and CA1 region (B). NMDA (50–150 nmol) reduced the number of neurons both in the cortex (C) and CA1 region (D). NMDA-reduced (150 nmol) neuron density was attenuated by pranlukast (0.1 mg/kg), edaravone (9 mg/kg) and ketamine (30 mg/kg) (E,F). Mean±SD. *n*=5–7 mice per group. <sup>c</sup>*P*<0.01 vs PBS group; <sup>e</sup>*P*<0.05, <sup>f</sup>*P*<0.01 vs control group (NMDA alone); one-way ANOVA. Scale bar=50 μm.

NMDA-induced brain injury is similar to ketamine and edaravone.

**CysLT<sub>1</sub> receptor mRNA expression after NMDA microinjection** NMDA (100 and 150 nmol) significantly increased the expression of the CysLT<sub>1</sub> receptor mRNA, in the injured region of the mouse brain 24 h after NMDA microinjection (*P*<0.05 or 0.01; Figure 3A, 3D), but NMDA at 50 nmol did not significantly affect the expression (data not shown). Pranlukast (0.1 mg/kg) and ketamine (30 mg/kg) significantly

inhibited NMDA (150 nmol)-increased expression of the CysLT<sub>1</sub> receptor mRNA (*P*<0.05) but edaravone did not show this effect (*P*>0.05; Figure 3F). Otherwise, in the corresponding contralateral region, the expression of the CysLT<sub>1</sub> receptor mRNA was not changed (Figure 3E). This result indicated that NMDA increased the expression of the CysLT<sub>1</sub> receptor mRNA, which was inhibited by the NMDA receptor antagonist ketamine and the CysLT<sub>1</sub> receptor antagonist, pranlukast, but not by the antioxidant edaravone.



**Figure 3.** CysLT<sub>1</sub> receptor mRNA expression and the effect of pranlukast 24 h after NMDA microinjection. mRNA was detected by RT-PCR. Upper panels show the representative results. NMDA (100 and 150 nmol) increased the expression of mRNA (A,D). NMDA-increased (150 nmol) expression was attenuated by pranlukast (0.1 mg/kg) and ketamine (C,F). However, no significant change was found in the contralateral hemisphere (B,E). Mean±SD. n=5–8 mice per group; <sup>b</sup>P<0.05, <sup>c</sup>P<0.01 vs PBS group; <sup>e</sup>P<0.05 vs control group (NMDA alone); one-way ANOVA. M, marker; 1, PBS; 2, NMDA injection (control); 3, pranlukast 0.01 mg/kg; 4, pranlukast 0.1 mg/kg; 5, edaravone 9 mg/kg; and 6, ketamine 30 mg/kg.


**Distribution of the CysLT<sub>1</sub> receptor immunopositive cells after NMDA microinjection** Western blotting analysis confirmed the specificity of a polyclonal rabbit anti-human CysLT<sub>1</sub> receptor antibody used in the mouse brain because the same bands were found in the mouse brain samples and the samples from cultured human umbilical vein endothelial cells (EA.hy926 cells) or human neuroblastoma SK-N-SH cells (Figure 4E). The band was closed to 43 kDa, which was consistent with previously published results using the same polyclonal antibody<sup>[27,28]</sup>. Using the antibody, we detected the distribution of CysLT<sub>1</sub> receptor protein 24 h after NMDA (150 nmol) microinjection by immunohistochemistry. The result showed that CysLT<sub>1</sub>-positive cells were significantly increased in the cortex and hippocampal CA1 region after NMDA excitotoxic damage (Figure 4A–4D), but not in the hippocampal CA3 or DG region. Pranlukast (0.1 mg/kg) and ketamine (30 mg/kg) reduced CysLT<sub>1</sub>-positive cells, but edaravone (9 mg/kg) did not show this effect (Figure 4A–4D). To determine whether the increased expression of the CysLT<sub>1</sub> receptor is distributed in neurons or astrocytes, we

performed double immunofluorescence. The result showed that CysLT<sub>1</sub> receptor immunoreactivity was mainly localized in NeuN-positive neurons in the NMDA (150 nmol)-injected cortex and hippocampal CA1 region (Figure 5). However, no apparent change was found in GFAP-positive astrocytes; the CysLT<sub>1</sub> receptor was much less expressed in the astrocytes (Figure 6).

**Discussion**

The most important finding in the present study is that the CysLT<sub>1</sub> receptor is involved in brain excitotoxicity. This involvement is evidenced by the upregulation of the CysLT<sub>1</sub> receptor after NMDA microinjection and the attenuation of NMDA insult by a CysLT<sub>1</sub> receptor antagonist, pranlukast. Therefore, our study shows a possible interaction between the excitotoxicity and the inflammation related to CysLT in the brain.

Our immunohistochemical results indicate that CysLT<sub>1</sub> receptor expression is induced by NMDA microinjection and




**Figure 4.** CysLT<sub>1</sub> receptor immunoreactive cells in the injured cortex and hippocampal CA1 region and the effect of pranlukast 24 h after NMDA microinjection. Representative microphotographs show the CysLT<sub>1</sub>-positive cells in the cortex (A) and CA1 region (C) from PBS control, NMDA (150 nmol) injection, edaravone-, pranlukast (0.01 and 0.1 mg/kg)- and ketamine-treated mice, and the data summarized (B, D). The specificity of an anti-human CysLT<sub>1</sub> receptor antibody used in this study was identified by Western blotting; the band was the same in the protein samples from the mouse brain and 2 human cell lines, human umbilical vein endothelial cells (EA.hy926 cells) and human neuroblastoma SK-N-SH cells (E). Mean±SD. *n*=6–8 mice per group. <sup>c</sup>*P*<0.01 vs NMDA alone; one-way ANOVA. nd, not detectable. Scale bar=50 μm.

mainly localized in the neurons, but not in the astrocytes in the injured regions. This finding is consistent with those of our recent studies. We found that the CysLT<sub>1</sub> receptor was primarily distributed in microvascular endothelial cells in the human brain, and an inducible expression was detected in the neuron- and glial-appearing cells in the brain specimens from patients with brain trauma or tumors<sup>[16]</sup>. In rats and mice with focal cerebral ischemia, CysLT<sub>1</sub> receptor expression was largely increased in the ischemic core 24 h after

ischemia, and the increased expression was mainly localized in NeuN-positive neurons and much less in GFAP-positive astrocytes (unpublished data). These findings suggest that the CysLT<sub>1</sub> receptor may mediate various brain injuries, such as trauma, ischemia and tumors, as well as chemically-induced excitotoxicity in the present study.

Interestingly, the increased CysLT<sub>1</sub> receptor expression induced by NMDA is not only inhibited by the NMDA receptor antagonist, ketamine, but also by the CysLT<sub>1</sub> recep-




**Figure 5.** Double immunofluorescence for detecting CysLT<sub>1</sub> receptor localization in neurons 24 h after NMDA (150 nmol) microinjection. CysLT<sub>1</sub> receptor immunoreactive cells (red) are mainly localized in NeuN-positive neurons (green) in the cortex and hippocampal CA1 region of the NMDA-injected hemisphere, but the CysLT<sub>1</sub> receptor immunoreactivity is very weak in the PBS-injected hemisphere. Scale bar= 50 μm.

tor antagonist, pranlukast. Since none of the agents affect the expression of a CysLT<sub>1</sub> receptor mRNA, in the contralateral brain region from the NMDA-treated mice, it can be excluded that ketamine or pranlukast directly inhibits the expression. Inhibition by ketamine reasonably results from the blockage of NMDA actions. However, why pranlukast also inhibits CysLT<sub>1</sub> receptor expression is unclear. One possible explanation might be that attenuation of brain injury by pranlukast may secondarily reduce CysLT<sub>1</sub> receptor expression; however, this explanation is not supported by the effect of edaravone that attenuated NMDA-induced injury, but did not inhibit the expression. Another explanation might be that this phenomenon may be a special effect of CysLT<sub>1</sub> receptor antagonists. We have found that montelukast, another CysLT<sub>1</sub> receptor antagonist, also inhibited CysLT<sub>1</sub>, but not CysLT<sub>2</sub> receptor mRNA expression in the lungs with eosinophilic inflammation from asthmatic

mice<sup>[29]</sup>. Because interleukin-5 (IL-5) upregulates CysLT<sub>1</sub> receptor expression<sup>[30]</sup> and pranlukast inhibits IL-5 production<sup>[29,31]</sup>, inhibition of CysLT<sub>1</sub> receptor expression by pranlukast might result from its effect on upregulation by IL-5.

Among the agents used in the present study, ketamine is applied to confirm NMDA receptor activation, pranlukast is to confirm CysLT<sub>1</sub> receptor activation, and edaravone is to distinguish the differences from pranlukast. Ketamine is a potent non-competitive NMDA receptor antagonist that has been shown to protect neurons from excitotoxic injury after cerebral ischemia<sup>[32,33]</sup>, trauma<sup>[34]</sup> or injection of excitotoxins<sup>[35,36]</sup>. In the present study, the inhibition of all the responses to NMDA by ketamine confirmed that NMDA-induced responses are mediated by NMDA receptor activation, similar to the reported results<sup>[36,37]</sup>. For the effect of pranlukast, we used 2 doses of pranlukast; 0.01 mg/kg was a nearly ineffective dose and 0.1 mg/kg was the most effective dose in





**Figure 6.** Double immunofluorescence for detecting CysLT<sub>1</sub> receptor localization in the astrocytes 24 h after NMDA (150 nmol) microinjection. CysLT<sub>1</sub> receptor immunoreactive cells (red) are much less localized in the GFAP-positive astrocytes (green) in the cortex and hippocampal CA1 regions of the PBS- or NMDA-injected hemisphere. Scale bar=50  $\mu$ m.

the experiments of cerebral ischemia<sup>[17,18,20]</sup>. The results showed dose-dependency; only 0.1 mg/kg exerts effect on brain injury. In addition, edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically available neuroprotective agent for the treatment of stroke with activity reducing free radicals<sup>[22,23,38,39]</sup>. We found that edaravone had a different effect from pranlukast; it attenuated NMDA-induced brain injury, similar to its neuroprotective effect on cerebral ischemia<sup>[23,38,39]</sup>, but did not affect CysLT<sub>1</sub> receptor expression. Therefore, this difference supports that the effect of pranlukast on CysLT<sub>1</sub> receptor expression might be special.

Excitotoxicity is a common injurious factor involved in many CNS diseases including cerebral ischemia. The present study indicates one aspect of the interaction between excitotoxicity and 5-LOX/CysLT pathway: the CysLT<sub>1</sub> recep-

tor is upregulated and plays a role in excitotoxicity. As another aspect, we recently found that 5-LOX was upregulated by excitotoxicity<sup>[12]</sup>. Taken together, excitotoxicity initiates post-injury inflammation by enhancing both pro-inflammatory molecules (like 5-LOX) and inflammatory responses (like strengthening the action of CysLT).

### Acknowledgments

We thank Dr Masami TSUBOSHIMA (Ono Pharmaceutical Co Ltd, Osaka, Japan) for providing us with pranlukast, Dr Cora-Jean S EDGELL (Pathology Department, University of North Carolina) for providing EA.hy926 cells, and Professor Jian-hong LUO, Department of Neurobiology, School of Medicine, Zhejiang University, for critically reading and commenting on this manuscript.

## References

- 1 Carlson NG, Wieggl WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. *J Immunol* 1999; 163: 3963–8.
- 2 Gucuyener K, Atalay Y, Aral YZ, Hasanoglu A, Turkyilmaz C, Biberoglu G. Excitatory amino acids and taurine levels in cerebrospinal fluid of hypoxic ischemic encephalopathy in newborn. *Clin Neurol Neurosurg* 1999; 101: 171–4.
- 3 Favalli L, Rozza A, Frattini P, Masoero E, Scelsi R, Pascale A, *et al*. Ischemia-induced glutamate release in rat frontoparietal cortex after chronic alcohol and withdrawal. *Neurosci Lett* 2002; 326: 183–6.
- 4 Galasso JM, Liu Y, Szaflarski J, Warren JS, Silverstein FS. Monocyte chemoattractant protein-1 is a mediator of acute excitotoxic injury in neonatal rat brain. *Neuroscience* 2000; 101: 737–44.
- 5 Jander S, Schroeter M, Stoll G. Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. *J Neuroimmunol* 2000; 109: 181–7.
- 6 Acarin L, Gonzalez B, Castellano B. Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage. *Stroke* 2002; 33: 2499–505.
- 7 Mabe H, Nagai H, Suzuka T. Role of brain tissue leukotriene in brain oedema following cerebral ischaemia: effect of a 5-lipoxygenase inhibitor, AA-861. *Neurol Res* 1990; 12: 165–8.
- 8 Baba T, Black KL, Ikezaki K, Chen KN, Becker DP. Intracarotid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats. *J Cereb Blood Flow Metab* 1991; 11: 638–43.
- 9 Rao AM, Hatcher JF, Kindy MS, Dempsey RJ. Arachidonic acid and leukotriene C4: role in transient cerebral ischemia of gerbils. *Neurochem Res* 1999; 24: 1225–32.
- 10 Ciceri P, Rabuffetti M, Monopoli A, Nicosia S. Production of leukotrienes in a model of focal cerebral ischaemia in the rat. *Br J Pharmacol* 2001; 133: 1323–9.
- 11 Di Gennaro A, Carnini C, Buccellati C, Ballerio R, Zarini S, Fumagalli F, *et al*. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. *FASEB J* 2004; 18: 842–4.
- 12 Ge QF, Wei EQ, Zhang WP, Hu X, Huang XJ, Zhang L, *et al*. Activation of 5-lipoxygenase after oxygen-glucose deprivation is partly mediated via NMDA receptor in rat cortical neurons. *J Neurochem* 2006; 97: 992–1004.
- 13 Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Nicosia S, *et al*. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. *Pharmacol Rev* 2003; 55: 195–227.
- 14 Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, *et al*. Characterization of the human cysteinyl leukotriene CysLT1 receptor. *Nature* 1999; 399: 789–93.
- 15 Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, *et al*. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. *Mol Pharmacol* 1999; 56: 657–63.
- 16 Zhang WP, Hu H, Zhang L, Ding W, Yao HT, Chen KD, *et al*. Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. *Neurosci Lett* 2004; 363: 247–51.
- 17 Zeng LH, Zhang WP, Wang RD, Wang PL, Wei EQ. Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice. *Yao Xue Xue Bao* 2001; 36: 148–50. Chinese.
- 18 Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. *Acta Pharmacol Sin* 2002; 23: 871–7.
- 19 Zhang LH, Wei EQ. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. *Acta Pharmacol Sin* 2003; 24: 1241–7.
- 20 Yu GL, Wei EQ, Zhang SH, Xu HM, Chu LS, Zhang WP, *et al*. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. *Pharmacology* 2005; 73: 31–40.
- 21 Zhang LH, Wei EQ. ONO-1078 reduces NMDA-induced brain injury and vascular cell adhesion molecule-1 expression in rats. *Acta Pharmacol Sin* 2005; 26: 435–40.
- 22 Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, *et al*. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. *J Neurol Sci* 2004; 221: 11–7.
- 23 Yasuoka N, Nakajima W, Ishida A, Takada G. Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats. *Dev Brain Res* 2004; 151: 129–39.
- 24 Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, *et al*. Reduced susceptibility to ischemic brain injury and *N*-methyl-*D*-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. *Proc Natl Acad Sci USA* 2001; 98: 1294–9.
- 25 Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. *Stroke* 1993; 24: 117–21.
- 26 Ogasawara H, Ishii S, Yokomizo T, Kakinuma T, Komine M, Tamaki K, *et al*. Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution. *J Biol Chem* 2002; 277: 18763–8.
- 27 Mazzetti L, Franchi-Micheli S, Nistri S, Quattrone S, Simone R, Ciuffi M, *et al*. The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells. *Br J Pharmacol* 2003; 138: 707–15.
- 28 Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. *Gastroenterology* 2003; 124: 57–70.
- 29 Zhang YJ, Zhang L, Wang SB, Shen HH, Wei EQ. Montelukast modulates lung CysLT1 receptor expression and eosinophilic inflammation in asthmatic mice. *Acta Pharmacol Sin* 2004; 25: 1341–6.
- 30 Thivierge M, Doty M, Johnson J, Stankova J, Rola-Pleszczynski M. IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. *J Immunol* 2000; 165: 5221–6.
- 31 Fukushima C, Matsuse H, Hishikawa Y, Kondo Y, Machida I, Saeki S, *et al*. Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from

- leukotriene receptor antagonism. *Int Arch Allergy Immunol* 2005; 136: 165–72.
- 32 Church J, Zeman S, Lodge D. The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. *Anesthesiology* 1988; 69: 702–9.
- 33 Proescholdt M, Heimann A, Kempfski O. Neuroprotection of S (+) ketamine isomer in global forebrain ischemia. *Brain Res* 2001; 904: 245–51.
- 34 Shapira Y, Lam AM, Eng CC, Laohaprasit V, Michel M. Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury. *Stroke* 1994; 25: 1637–43.
- 35 Leander JD, Lawson RR, Ornstein PL, Zimmerman DM. *N*-methyl-*D*-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs. *Brain Res* 1988; 448: 115–20.
- 36 Lees GJ. Influence of ketamine on the neuronal death caused by NMDA in the rat hippocampus. *Neuropharmacology* 1995; 34: 411–7.
- 37 Lees GJ. Effects of ketamine on the *in vivo* toxicity of quinolinate and *N*-methyl-*D*-aspartate in the rat hippocampus. *Neurosci Lett* 1987; 78: 180–6.
- 38 Wu TW, Zeng LH, Wu J, Fung KP. MCI-186: further histochemical and biochemical evidence of neuroprotection. *Life Sci* 2000; 67: 2387–92.
- 39 Ikeda T, Xia YX, Kaneko M, Sameshima H, Ikenoue T. Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats. *Neurosci Lett* 2002; 329: 33–6.
- 

## The 8th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2007

August 29 – September 1, 2007

Amsterdam, the Netherlands

<http://www.eacpt2007.nl/>